Fibromyalgia Treatment Market

Fibromyalgia Treatment Market Outlook (2024 to 2034)

The global fibromyalgia treatment market size is projected to grow from US$ 1,445.8 million in 2024 to US$ 2,830.1 million by 2034. Over the assessment period, demand for fibromyalgia treatment is projected to increase at 6.9% CAGR.

Demand remains exceptionally high for antidepressants and anticonvulsants in the market owing to their effectiveness in relieving chronic pain associated with fibromyalgia. The target segments are poised to record CAGRs of 7.9% and 6.4%, respectively, through 2034.

Currently, there is no proper cure for fibromyalgia. However, patients use different medications, including antidepressants, analgesics, and anticonvulsants, to ease symptoms and improve quality of life. This is expected to boost the growth of the global fibromyalgia treatment market through 2034.

Fibromyalgia treatment drugs help to relieve the musculoskeletal pain associated with fibromyalgia. They can also improve sleep and emotional health. As a result, their demand is anticipated to rise significantly amid growing cases of fibromyalgia.

The market is also witnessing a transition toward targeted therapies as well as non-pharmacological treatments like physical therapy and cognitive behavior therapy. This will likely foster revenue growth during the assessment period.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 1,445.8 million
Projected Market Value (2034F)	US$ 2,830.1 million
Global Market Growth Rate (2024 to 2034)	6.9% CAGR
Anticonvulsants Segment Market Share (2034)	52.6%
Online Pharmacies Segment Growth Rate (2024 to 2034)	8.6%
North America Market Share (2034)	39.9%
East Asia Market Share (2034)	21.2%
Key Companies Profiled	FSD Pharma AbbVie, Inc. Pfizer, Inc. Sanofi Bayer AG GlaxoSmithKline plc. Teva Pharmaceutical Industries Ltd. Aptinyx Inc. Johnson & Johnson Services, Inc. Virios Therapeutics, Inc. TONIX Pharmaceutical Holdings Corp Eli Lilly and Company.

Fibromyalgia Treatment Market Analysis

Which Factors Are Fueling Fibromyalgia Treatment Demand?

“Increasing Incidence of Fibromyalgia Globally”

Over the years, there has been a sharp rise in cases of fibromyalgia, a somatization disorder characterized by symptoms like musculoskeletal pain and pain. For instance, as per the National Health Services, around 1 in 20 people globally suffer from fibromyalgia.

Patients who have fibromyalgia often opt for medications like antidepressants and anticonvulsants to relieve pain and other symptoms. Hence, the growing prevalence of fibromyalgia is expected to fuel demand for fibromyalgia therapy during the assessment period.

“Rise in Diagnostic Screen of Fibromyalgia”

Rising awareness and understanding of fibromyalgia among the general public and healthcare professionals is leading to higher diagnostic rates. This, in turn, is expected to generate high demand for fibromyalgia treatments, including medications, cognitive behavior therapy, and acupuncture, among others.

Fibromyalgia medications help to reduce pain, fatigue, and other symptoms of fibromyalgia. Similarly, talking therapies can help to address symptoms like fibro fog. Hence, increasing diagnostic rates of fibromyalgia is predicted to boost the fibromyalgia treatment market growth.

What are the Key Fibromyalgia Treatment Market Trends?

“Introduction of Novel Fibromyalgia Medications and Technologies”

Although there is no permanent cure for fibromyalgia, several drugs help to reduce its symptoms and improve the patient’s quality of life. This is prompting top pharmaceutical companies and research institutes to explore novel fibromyalgia therapies or medications.

New research is being undertaken to study the underlying mechanism of fibromyalgia, leading to the development of new experimental drugs as well as combination therapies. The introduction of new medications or therapies for the management of fibromyalgia is expected to positively impact the global fibromyalgia treatment industry.

Innovations remain at the heart of the fibromyalgia treatment industry. Companies are looking to introduce new fibromyalgia treatment approaches to stay ahead of the competition. For instance, in September 2022, Swing Therapeutics introduced Stanza in the United States.

It is the first digital therapy for fibromyalgia patients. Subsequently, the company received Novo marketing authorization from the FDA from Stanza in May 2023.

Similarly, in November 2022, NeuroMetrix launched Quell Fibromyalgia. It is a wearable neuromodulation technology that is the first and only FDA-authorized medical device to help reduce fibromyalgia symptoms.

The adoption of digital health technologies like wearable devices and mobile apps is expanding the management of fibromyalgia. This is projected to further boost sales growth during the assessment period.

Which Factors Are Limiting Market Expansion?

“Limited Availability of Approved Medications and Side Effects of Fibromyalgia Drugs”

Despite a strong growth prediction, certain factors can limit the expansion of the global fibromyalgia treatment industry. One such factor is the limited availability of approved medications for fibromyalgia treatment.

A limited number of medications are approved by regulatory bodies like the Food and Drug Administration (FDA). As a result, people suffering from fibromyalgia often require off-label treatment, thereby limiting market expansion.

Another factor restraining the growth of the fibromyalgia treatment industry is the side effects of several fibromyalgia drugs. Subsequently, the growing popularity of alternative treatment approaches can negatively impact the market.

Medications like antidepressants (SSRIs) often result in symptoms like tremors, sexual problems, increased heart rate, and others. As a result, several patients refrain from using them.

Country-wise Insights

North America is anticipated to remain at the top of the ladder in the fibromyalgia treatment market, while East Asia is expected to offer lucrative growth opportunities to manufacturers. This is due to the increasing patient pool and the strong presence of pharmaceutical giants.

The East Asia fibromyalgia treatment market is projected to expand with a robust CAGR of 10.3% during the forecast period. It will likely hold a global market share of about 21.2% in 2034, with China and Japan at the forefront.

The North America fibromyalgia treatment industry is projected to register a CAGR of 5.4% over the assessment period. It is set to hold a global market share of 39.9% by 2034, with the United States becoming the hotbed for key players.

What is Propelling Fibromyalgia Treatment Demand in the United States?

“Rising Prevalence of Fibromyalgia Driving Demand in the United States”

The United States fibromyalgia treatment market value is expected to total US$ 939 million in 2034. Over the forecast period, demand for fibromyalgia treatment in the United States is projected to grow at 5.2% CAGR.

Several factors are expected to drive the growth of the fibromyalgia treatment industry in the United States. These include a growing incidence of fibromyalgia, rising preference for personalized treatment, availability of generics, and high level of health awareness among people.

There has been a spike in cases of fibromyalgia in the United States during the last few years. As per the National Fibromyalgia Association (NFA), fibromyalgia affects an estimated 10 million people in the United States. This, in turn, is driving demand for fibromyalgia treatment, and the trend will likely continue through 2034.

The United States is also home to several leading pharmaceutical giants. These companies are striving to develop novel medications targeting specific pain pathways and neurotransmitter regulation. This is expected to improve the United States fibromyalgia treatment market share.

Another key factor anticipated to boost the United States market is the development of new fibromyalgia therapies. Subsequently, increasing the number of fibromyalgia clinics will benefit the target industry.

What is the China Fibromyalgia Treatment Market Forecast?

“Growing Awareness of Fibromyalgia Boosting Market Growth in China”

China’s fibromyalgia treatment market is poised to expand from US$ 106 million in 2024 to US$ 313 million by 2034. Overall sales of fibromyalgia treatment medication in China will likely soar at 11.4% CAGR during the forecast period.

The diagnosis rate of fibromyalgia is rising significantly across China due to growing awareness and increasing government initiatives. This leads to a large pool of patients seeking fibromyalgia treatments, thereby fostering market growth.

The rising geriatric population is another key factor expected to fuel sales of fibromyalgia treatment drugs in China. Similarly, increasing the incidence of rheumatic diseases and traumatic stress disorder will likely benefit the target market.

Category-wise Insights

The below section provides a key into leading segments, their growth projections, and respective shares in the fibromyalgia treatment industry. Based on drug class, the anticonvulsants segment is expected to lead the market, holding a value share of 52.6% in 2034. By distribution channel, the hospital pharmacies segment is estimated to account for a prominent market share of 45.7% in 2024.

Which is the Most Effective Drug Class for Fibromyalgia Treatment?

“Anticonvulsants Remain Widely Accepted Drug Class for Fibromyalgia Treatment”

As per the latest analysis, anticonvulsants are expected to remain highly sought-after drugs for the treatment of fibromyalgia. This is due to their effectiveness in relieving fibromyalgia pain.

Demand for anticonvulsants in fibromyalgia management is poised to grow at 6.4% CAGR during the assessment period. It will likely total US$ 1,488.5 million, contributing a revenue share of 52.6% by 2034.

Anticonvulsants, also known as antiseizure medications or antiepileptic drugs, are gaining wider popularity for fibromyalgia treatment. These medications are used to treat different symptoms of fibromyalgia, including pain and sleep difficulties.

Patients who have fibromyalgia are opting for anticonvulsants like pregabalin and gabapentin to reduce pain. Thes medications are gaining huge traction in chronic pain treatment. Thus, increasing consumption of anticonvulsants for treating fibromyalgia symptoms will likely boost the target segment through 2034.

Which Distribution Channel will Contribute Most to the Market?

“Hospital Pharmacies Witnessing High Sales of Fibromyalgia Treatment Drugs”

Based on the distribution channel, the hospital pharmacies segment is expected to lead the global market, holding a share of 45.7% in 2024. Over the forecast period, the target segment is projected to grow at a CAGR of 5.9%.

Multiple factors are driving the growth of the hospital pharmacies segment. These include ease of accessibility to drugs and generics and a high hospital patient pool. Similarly, hospital pharmacies dominate this industry because of their well-established infrastructure and proficiency in fibromyalgia treatment drugs.

Patients suffering from fibromyalgia often have comorbidities like chronic pain, anxiety, and fatigue. As a result, they visit hospitals regularly and find it convenient to pick up their fibromyalgia medication from hospital pharmacies.

Competitive Landscape

Key players in the fibromyalgia treatment market include FSD Pharma, AbbVie, Inc., Pfizer, Inc., Sanofi, Bayer AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Aptinyx Inc., Johnson & Johnson Services, Inc., Virios Therapeutics, Inc., TONIX Pharmaceutical Holdings Corp, and Eli Lilly and Company.

Key manufacturers of fibromyalgia treatment drugs are investing rigorously in research and development to explore new & effective fibromyalgia drugs. They are also looking to get fast-track drug approval from regulatory bodies like the United States Food and Drug Administration (FDA).

Several companies also adopt strategies like partnerships, alliances, distribution agreements, facility expansions, collaborations, and acquisitions. These strategies are expected to enable them to expand their footprint and significantly stay ahead of the competition.

Recent Developments in the Fibromyalgia Treatment Market-

• In April 2021, FSD Pharma Inc. acquired the Canada-based specialty psychedelic pharmaceutical business Lucid Psycheceuticals Inc.
• In October 2023, NeuroMetrix, Inc. collaborated with the National Fibromyalgia Association to improve the quality of life of patients with fibromyalgia.
• In December 2023, AbbVie Inc. collaborated with BigHat Biosciences to discover and develop next-generation therapeutic antibodies in neuroscience and oncology.
• In January 2020, Axsome Therapeutics entered into an agreement with Pfizer Inc. for Prizer’s Reboxetine clinical and nonclinical data. Under this agreement, Axsome also received the exclusive right to develop and commercialize esreboxetine, a novel late-stage product, in the United States for the treatment of fibromyalgia.

Fibromyalgia Treatment Market Segmentation

• By Drug Class:

  • Antidepressants
  • Anticonvulsants
  • Muscle Relaxants
  • Analgesics

• By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

• By Region:

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa